Victoria Socha

DocwireNews

Yorg Al Azzi, MD, and colleagues at Montefiore Medical Center, Bronx, New York, conducted an analysis to examine the variation in mortality from SARS-CoV-2 infection in kidney transplant recipients during the course of the pandemic. Results were reported during a poster session at the American Society of Nephrology Kidney Week 2022 in a poster titled Decreased Mortality From SARS-CoV-2 in Kidney Transplant Recipients Over the Course of the Pandemic.During the study period of March 16, 2020, to May 4, 2022, a total of 537 patients at the center were diagnosed with SARS-CoV-2 infection by reverse transcription polymerase chain reaction test. Of the 537 patients, 59% were male, median age was 58 years, 51.2% were Hispanic, and 29% were African American. Three-quarters (75.4%) had received a deceased-donor renal transplant and 55% received anti-thymocyte induction. Most of the patients were on triple immunosuppression (96% calcineurin inhibitors, 87% antimetabolite, and 99% on prednisone).During the first peak of the pandemic (March 16-April 30, 2020), the mortality rate was 35% (n=47/128). The mortality rate significantly decreased to 11% (n=7/61) from May 1, 2020, to the end of December 2020 with social distancing and use of face masks. With the introduction of <a href="https://www.docwirenews.com/nephtimes/nephtimes-diseases-and-conditions/sars-cov-2-vaccine-response-in-kidney-transplant-recipients/">vaccines</a> and monoclonal antibodies, the mortality rate further declined to 7.7% (n=10/129) between January 1, 2021, and November 5, 2021. When the Omicron variant and subvariants were predominant (November 6, 2021, to&nbsp;&nbsp; May 4, 2022) the mortality rate was 5.5% (n=12/219).Among the patients diagnosed during the Omicron predominant wave, 85.8% (n=188/219) had received two doses of COVID-19 vaccine and 37.4% (n=82/219) had received a third dose. After introduction of the use of monoclonal antibodies, 93 patients received a combination of casirivimab/ imdevimab during the period of the initial SARS-CoV-2 variants and sotrovimab then bebtelovimab during the time of dominance of Omicron and subvariants. Only one death occurred in the group that received monoclonal antibody treatment; that patient had been hospitalized for severe COVID-19.There were 23 reinfections in the study cohort. Most of the reinfected patients had received at least two doses of COVID-19 vaccine; only five received a third dose. None of the patients who were reinfected required hospitalization or died.In summary, the authors said, &ldquo;Mortality from SARS-CoV-2 infection in kidney transplant recipients has significantly decreased over time. This could be explained by initial exposure to higher viral load due to lack of personal protection and social distancing. However, since the judicious use of monoclonal antibodies and vaccination, in addition to social distancing and use of face masks, the mortality in kidney transplant recipients has decreased over time.&rdquo;Source: Al Azzi Y, Liriano-Ward LE, Kapoor S, Ajaimy M, Akalin E, Pynadath CT. Decreased mortality from SARS-CoV-2 in kidney transplant recipients over the course of the pandemic. TH-PO945. Abstract of a poster presented during the American Society of Nephrology Kidney Week 2022; November 3, 2022; Orlando, Florida.

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Hatem Soliman, MD

Using Dendritic Cell Vaccines to Boost Neoadjuvant Therapy in HER2+ Breast Cancer

HER2 Breast Cancer

Kathleen Liu, MD

Joel M. Topf, MD, FACP

AKI Approaches and ASN Kidney Health Guidance

NKF Spring Clinical Meetings 2025

Latest News

Mortality From COVID-19 Infection in Kidney Transplant Recipients Over Time

COVID-19 and Kidney Disease

Yorg Al Azzi, MD, and colleagues at Montefiore Medical Center, Bronx, New York, conducted an analysis to examine the variation in mortality from SARS-CoV-2 infection in kidney ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe